Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
68
-
Total 13F shares, excl. options
-
13.9M
-
Shares change
-
+1.99M
-
Total reported value, excl. options
-
$93.6M
-
Value change
-
+$10.9M
-
Number of buys
-
41
-
Number of sells
-
-37
-
Price
-
$6.72
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q2 2018
85 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q2 2018.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 68 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.9M shares
of 61.4M outstanding shares and own 22.69% of the company stock.
Largest 10 shareholders include FMR LLC (3.18M shares), GREAT POINT PARTNERS LLC (1.47M shares), BVF INC/IL (1.42M shares), FARALLON CAPITAL MANAGEMENT LLC (910K shares), Pharmstandard International S.A. (751K shares), VANGUARD GROUP INC (517K shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (500K shares), RENAISSANCE TECHNOLOGIES LLC (478K shares), Cormorant Asset Management, LP (382K shares), and DEUTSCHE BANK AG\ (294K shares).
This table shows the top 68 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.